Q1 2022 PCI Biotech Holding ASA Earnings Call Transcript
Good morning, and welcome to PCI Biotech First Quarter 2022 Presentation. My name is Per Walday. I'm the CEO of PCI Biotech, and I have with me today also Ronny Skuggedal, who is the CFO; and Amir Snapir, who is the CMO. After the presentation, we will have a Q&A session, which will be through both the teleconference and the webcast console. So please pay attention to the details here. If you want to ask a question, you need to call in and do this if you want to do it verbally. Otherwise, please use the webcast. Also, please pay attention to this important notice and disclaimer.
So what we are going to review today, first, to start with the highlights of the first quarter '22 and then an operational review, the clinical and preclinical programs and then ending it with key financials and outlook before we have the question-and-answer session afterwards.
So let me start by going through the highlights. So fimaVACC is our lead program now, and this is progressing towards initiation of a Phase II clinical proof-of-concept study. This study has a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
